For Health Care Professionals Outside the US

 
 
 

Discontinuation rates

FARYDAK discontinuation rates

Discontinuation due to adverse events, regardless of causality, was observed in 36.2% of patients.2

References:

  1. Data on file. Clinical study report CLBH589D2308. Novartis Pharmaceuticals Corp; Feb 2014.
  2. FARYDAK® (panobinostat). EU Summary of Product Characteristics. Novartis AG; April 2016.